Overview
Thomas Steindler is counsel for Novartis in an IP dispute where a competitor is attempting to overturn Novartis’ hepatitis C patents. A California federal judge has sent the suit to arbitration, finding that uncertainties in a licensing agreement between the companies triggers a presumption in favor of the Federal Arbitration Act.
